Gemvax as

Targovax Asa

Norsk Hydro, A.s.

Lytix Biopharma as

Hubro Therapeutics as

Jon Amund Eriksen

Gustav Gaudernack

Mona Møller

Marianne Klemp Gjertsen

Ingvil Sæterdal

Ingvil Saeterdal

Stein Sæbøe-Larssen

Stein Sæbøe-Larsen

Mona Moller

Stein Saeboe-Larssen

John Sigurd Svendsen

Øystein Rekdal

Oystein Rekdal

Bengt Erik Haug

Ingvil S&aelig;terdal

Tobias Gedde-Dahl

Stein Sæøe-Larssen

Gustay Gaudernack

Mona M&oslash;ller

ØYstein Rekdal

Mona Moeller

There is disclosed a peptide mixture suitable for eliciting an immune response. It comprises a first and a second peptide, each corresponding to a fragment of the RAS protein. Each of the first and second peptides comprises a region of at least 8 amino acids which includes position 13 of the RAS protein. Each of said regions of the first and second peptides independently has at least 6 amino acid residues, other than at said position 13, which are identical to the corresponding region of the RAS protein. Each of the first and the second peptides has a point mutation at the amino acid corresponding to said position 13. The point mutation of the first peptide is different from the point mutation of the second peptide.

Peptide mixture

There is disclosed at least one peptide suitable for eliciting an immune response, for use in the treatment of cancer. The, or each, peptide corresponds to a fragment of the RAS protein, but has one to three point mutations thereof. The at least one peptide is for use in the treatment of cancer by simultaneous or sequential administration with an anti-metabolite chemotherapeutic agent.

Peptide vaccine comprising mutant RAS peptide and chemotherapeutic agent

The present invention relates to peptides or peptide like molecules and their uses in therapy, in particular as anti-tumor agents.

Nonapeptide with anti-tumour activity

Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the inventions are also described.

Peptides

The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognizing and destroying tumor cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.

Nucleic acids encoding novel TERT polypeptides

Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the invention are also described.

This invention relates to proteins or peptides that elicit T cell mediated immunity, and to cancer vaccines and compositions for anti-cancer treatment comprising such proteins or peptide fragments. This invention also relates to pharmaceutical compositions comprising the proteins or peptides and methods for generating T lymphocytes capable of recognizing and destroying tumor cells in a mammal. More specifically, a telomerase protein or peptide for use in a method of treatment or prophylaxis of cancer is provided. In a preferred embodiment, the method comprises generating a T cell response against telomerase.

Antigenic peptides derived from telomerase

Polypeptides

The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognising and destroying tumour cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.

Frameshift Mutants &#x3b2;-Amyloid precursor peptides and mutant ubiquitin-B associated with Alzheimer's disease and Down syndrome eliciting T cellular immunity for use in compositions for the treatment and/or prophylaxis of Alzheimer's disease and/or Down syndrome.

Growing community of inventors

Porsgrunn, Norway

Jon Amund Eriksen